search

Active clinical trials for "Dyskinesias"

Results 1-10 of 254

Transcranial Direct Current Stimulation of the Primary Motor Cortex to Treat Levodopa-induced Dyskinesias...

Parkinson Disease

The main objective of the study is to evaluate the efficacy of 10 sessions of transcranial direct current stimulation of the primary motor cortex to reduce levodopa-induced dyskinesia

Recruiting8 enrollment criteria

Study Evaluating the Safety and Tolerability of RCT1100 in Healthy Subjects

Primary Ciliary Dyskinesia

This is the first-in-human study with RCT1100 and is designed to provide initial safety and tolerability data for future clinical studies.

Recruiting11 enrollment criteria

A Study in Parkinson's Disease in Patients With Moderate to Severe Dyskinesia

Dyskinesias

The current study will explore the efficacy, safety and tolerability of 2 dose combinations of JM-010 to determine the optimal doses of each component to be studied in confirmatory clinical trials.

Recruiting15 enrollment criteria

A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in...

Huntington DiseaseTardive Dyskinesia

This is a single-center, randomized, double-blinded, placebo-controlled, dose escalation trial to evaluate the safety, tolerability and pharmacokinetic of LPM3770164 sustained-release tablets orally administered in healthy subjects under fasting state, providing the rationale information for subsequent clinical trials.

Recruiting22 enrollment criteria

Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants...

SchizophreniaSchizoaffective Disorder3 more

This study will evaluate the effectiveness of valbenazine on patient- and clinician-reported outcomes assessing health-related quality of life, functioning, and treatment effect in participants with tardive dyskinesia (TD) who are receiving valbenazine for up to 24 weeks.

Recruiting9 enrollment criteria

Effects of Rhythmic Auditory Stimulation on Movements in Individuals at Risk for Psychotic Onset...

SchizophreniaPsychosis2 more

The purpose of this research is to examine effects of movement training with the aid of rhythmic auditory stimulation (RAS) on reducing severity of dyskinesia and bradykinesia in at-risk individuals and schizophrenia patients. The investigators hypothesize that training with the aid of RAS reduced severity of bradykinesia and dyskinesia in at-risk individuals as well as in schizophrenia patients.

Recruiting27 enrollment criteria

The Effect of a Dietary Supplement Rich in Nitric Oxide in Patients Diagnosed With Primary Ciliary...

Primary Ciliary Dyskinesia

The purpose of this study is to determine the effect of a dietary supplement rich in nitric oxide (NO) on nasal nitric oxide and fractional exhaled nitric oxide (FeNO),on ciliary beat frequency assessed by high-speed digital video microscopy and on lung function assessed by spirometry in normal patients and patients with Primary ciliary dyskinesia (PCD).

Recruiting8 enrollment criteria

Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia...

DyskinesiaCerebral Palsy

The primary objective of this study is to evaluate the efficacy of valbenazine versus placebo on improving chorea in participants aged 6 to 70 years who have dyskinesia due to cerebral palsy (DCP) with choreiform movements.

Recruiting11 enrollment criteria

Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving...

Parkinson DiseaseDyskinesia2 more

This open-label study is designed to assess the long-term safety and tolerability of dipraglurant in PD patients for up to 52 weeks (at doses of 150-300 mg per day) for patients that have completed an Addex sponsored double-blind clinical trial of dipraglurant.

Recruiting9 enrollment criteria

Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based...

Parkinson DiseaseDyskinesia2 more

This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and 11 weeks at 300 mg per day). The primary efficacy assessment will be based on the Unified Dyskinesia Rating Scale (UDysRS). Patients who complete the 12-week blinded treatment period may have the option to roll into an open-label safety extension study for an additional 12-month treatment period.

Recruiting8 enrollment criteria
12...26

Need Help? Contact our team!


We'll reach out to this number within 24 hrs